DT Capital Partners, established in 2006, is a Shanghai-based venture capital and private equity firm. It specializes in providing growth capital to early and expansion-stage companies, primarily in China. The firm invests across various sectors, including advanced manufacturing, technology, healthcare, and clean energy. DT Capital Partners is known for its extensive experience in operating capital markets, close relationships with local governments, and synergies with other investment companies. It manages over USD$500 million across multiple funds and has a close affiliation with Madrone Capital in the US. The firm was recognized as one of China's top venture capital institutions in 2016.
Changle Road, Xuhui District, Shanghai 989, Century Business Plaza, Room 4201-4205 Zip Code: 200031, China / No.1 Gao Lan Road, Shanghai 200020, China
Yu Jiani
Partner
Past deals in Nanotechnology
Newmut Nanotechnology
Series B in 2025
Newmut Nano is a company with advanced technology in the domains of vapor deposition and high-temperature treatment reaction equipment both domestically and internationally. The principal products are experimental-grade and mass-production-grade fluidized bed reactors (FB-CVD), which are primarily employed in the manufacturing of carbon nanotube powder and the CVD coating of silicon-based anodes for lithium batteries.
Guoshun Laser
Series A in 2025
Guoshun Laser is a developer of high-power ultrafast micro-nano structure fiber lasers.
AccuraGen
Series B in 2016
AccuraGen Inc., founded in 2013 and located in Menlo Park, California, specializes in developing sequencing-based systems for detecting cancer mutations. The company has created a high-sensitivity technology that utilizes next-generation sequencing to identify cancer-related mutations in small amounts of circulating cell-free DNA (cfDNA) found in blood samples. This innovative approach addresses challenges in analyzing cfDNA by employing proprietary molecular biology techniques and computational algorithms that enhance error suppression. AccuraGen's system can amplify nanogram quantities of highly fragmented cfDNA over 1000-fold, allowing for the screening of a wide array of cancer-related genes with exceptional sensitivity, including at the single-digit molecular level. This technology aims to improve personalized cancer treatment by providing oncologists and clinicians with reliable molecular diagnostic capabilities.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.